Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are predictive markers for bevacizumab

Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are... Antiangiogenic agents such as bevacizumab that target the vascular endothelial growth factor (VEGF) pathway have shown promise in the treatment of a variety of malignancies.1 However, clinical biomarkers are needed for quantitative evaluation of the effect of bevacizumab.VEGF is known to promote the mobilization of bone‐marrow–derived circulating endothelial progenitors (CEPs) and survival by activating antiapoptotic pathways in circulating endothelial cells (CECs),2–4 which may subsequently differentiate into mature endothelial cells.5, 6 Recently, CEPs were reported to be involved in tumor angiogenesis in tumor implantation models7–10 and in clinical studies.11, 12 According to several clinical reports, baseline CEC levels in cancer patients have shown higher values compared with those in healthy controls and were correlated with response and outcome.13–15The aim of this study was to investigate the potential of CEPs and phenotypical CECs as surrogate markers of clinical outcome in metastatic colorectal cancer (mCRC) patients to identify responders to chemotherapy with bevacizumab.MATERIALS AND METHODSPatientsPrincipal inclusion criteria were measurable mCRC and commencement of a new systemic therapy. Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate organ function, and radiographic evidence of disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Wiley

Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are predictive markers for bevacizumab

Download PDF
7 pages

Loading next page...
 
/lp/wiley/circulating-endothelial-progenitors-and-cxcr4-positive-circulating-NaexMl5EQ2

References (29)

Publisher
Wiley
Copyright
Copyright © 2011 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0008-543X
eISSN
1097-0142
DOI
10.1002/cncr.25977
pmid
21858803
Publisher site
See Article on Publisher Site

Abstract

Antiangiogenic agents such as bevacizumab that target the vascular endothelial growth factor (VEGF) pathway have shown promise in the treatment of a variety of malignancies.1 However, clinical biomarkers are needed for quantitative evaluation of the effect of bevacizumab.VEGF is known to promote the mobilization of bone‐marrow–derived circulating endothelial progenitors (CEPs) and survival by activating antiapoptotic pathways in circulating endothelial cells (CECs),2–4 which may subsequently differentiate into mature endothelial cells.5, 6 Recently, CEPs were reported to be involved in tumor angiogenesis in tumor implantation models7–10 and in clinical studies.11, 12 According to several clinical reports, baseline CEC levels in cancer patients have shown higher values compared with those in healthy controls and were correlated with response and outcome.13–15The aim of this study was to investigate the potential of CEPs and phenotypical CECs as surrogate markers of clinical outcome in metastatic colorectal cancer (mCRC) patients to identify responders to chemotherapy with bevacizumab.MATERIALS AND METHODSPatientsPrincipal inclusion criteria were measurable mCRC and commencement of a new systemic therapy. Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate organ function, and radiographic evidence of disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).

Journal

Cancer – Wiley

Published: Sep 1, 2011

Keywords: circulating endothelial progenitors; CXCR4‐positive circulating endothelial cells; bevacizumab; metastatic colorectal cancer; chemotherapy

There are no references for this article.